CapsoVision (NASDAQ:CV) reported steady first-quarter revenue and said it continues to advance artificial intelligence and capsule endoscopy programs aimed at expanding the use of its gastrointestinal imaging platform.
On the company’s first-quarter 2026 earnings call, President and Chief Executive
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Roth Capital Partners acted as joint book-running manager for the initial public offering of CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company focused on AI-powered capsule endoscopy solutions. CapsoVision offered 5,500,000 shares of common stock at $5.00 per share, with gross proceeds totaling approximately $27.5 million before deductions. The shares began trading on the Nasdaq Capital Market on July 2, 2025, under the ticker symbol “CV.” The company also granted underwriters a 30-day option to purchase up to an additional 825,000 shares at the IPO price.
